Clinical Trial SuccessThe ongoing Ph. IIb trial with enobosarm aims to deliver leading muscle preservation and functional benefits, setting it apart in the field of obesity and muscle therapeutics.
Regulatory ProspectsEnobosarm remains the front-runner in demonstrating clinical lean mass improvements in GLP1-driven lean mass loss, which could lead to regulatory discussions and potential partnerships.
Strategic Business MovesVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.